JP2023519931A - 癌を治療するための方法及び組成物 - Google Patents

癌を治療するための方法及び組成物 Download PDF

Info

Publication number
JP2023519931A
JP2023519931A JP2022559338A JP2022559338A JP2023519931A JP 2023519931 A JP2023519931 A JP 2023519931A JP 2022559338 A JP2022559338 A JP 2022559338A JP 2022559338 A JP2022559338 A JP 2022559338A JP 2023519931 A JP2023519931 A JP 2023519931A
Authority
JP
Japan
Prior art keywords
cancer
pkmyt1
amino
subunit
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022559338A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023519931A5 (enExample
Inventor
ハリソン，スティーブン
テイラー ブリュー，クリスティーン
デイビッド ウィンザー，マイケル
バナジー，サウラブ
ヨスト，ショーン
Original Assignee
エンジン バイオサイエンシズ プライベート リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エンジン バイオサイエンシズ プライベート リミテッド filed Critical エンジン バイオサイエンシズ プライベート リミテッド
Publication of JP2023519931A publication Critical patent/JP2023519931A/ja
Publication of JP2023519931A5 publication Critical patent/JP2023519931A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022559338A 2020-04-01 2021-03-31 癌を治療するための方法及び組成物 Pending JP2023519931A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063003736P 2020-04-01 2020-04-01
US63/003,736 2020-04-01
PCT/US2021/025230 WO2021202780A2 (en) 2020-04-01 2021-03-31 Methods and compositions for treating cancer

Publications (2)

Publication Number Publication Date
JP2023519931A true JP2023519931A (ja) 2023-05-15
JP2023519931A5 JP2023519931A5 (enExample) 2024-04-19

Family

ID=77927411

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022559338A Pending JP2023519931A (ja) 2020-04-01 2021-03-31 癌を治療するための方法及び組成物

Country Status (9)

Country Link
US (1) US20230149415A1 (enExample)
EP (1) EP4127722A4 (enExample)
JP (1) JP2023519931A (enExample)
KR (1) KR20230017167A (enExample)
CN (1) CN115769077A (enExample)
AU (1) AU2021249111A1 (enExample)
CA (1) CA3173799A1 (enExample)
MX (1) MX2022012181A (enExample)
WO (1) WO2021202780A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240398799A1 (en) * 2021-08-19 2024-12-05 Engine Biosciences Pte. Ltd. Compositions and methods for generating synthetic lethality in tumors
WO2023177356A2 (en) * 2022-03-18 2023-09-21 Engine Biosciences Pte. Ltd. Compounds and method for pkmyt1 inhibition
KR20250136774A (ko) * 2024-03-08 2025-09-16 보로노이 주식회사 헤테로아릴 유도체 화합물 및 이의 용도
WO2025215187A1 (en) 2024-04-11 2025-10-16 My-T Bio Limited Therapeutic compounds and their use
WO2025215188A1 (en) 2024-04-11 2025-10-16 My-T Bio Limited Therapeutic compounds and their use as inhibitors of pkmyt1
WO2025242880A1 (en) 2024-05-24 2025-11-27 My-T Bio Limited Therapeutic compounds and their use
WO2026057597A1 (en) 2024-09-10 2026-03-19 My-T Bio Limited Pkmyt1 inhibitors and their use
WO2026057598A1 (en) 2024-09-10 2026-03-19 My-T Bio Limited Therapeutic compounds as pkmyt1 inhibitors and their use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018518522A (ja) * 2015-06-23 2018-07-12 ケース ウエスタン リザーブ ユニバーシティ 癌を治療するための組成物及び方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009002607A1 (en) * 2007-05-01 2008-12-31 Dana-Farber Cancer Institute, Inc. Compositions and methods for identifying transforming and tumor suppressor genes
RS56680B1 (sr) * 2012-11-28 2018-03-30 Merck Sharp & Dohme Kompozicije i postupci za lečenje kancera

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018518522A (ja) * 2015-06-23 2018-07-12 ケース ウエスタン リザーブ ユニバーシティ 癌を治療するための組成物及び方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CANCER MANAGEMENT AND RESEARCH, vol. 11, JPN6025015436, 2019, pages 7813 - 7824, ISSN: 0005574893 *

Also Published As

Publication number Publication date
WO2021202780A2 (en) 2021-10-07
EP4127722A4 (en) 2024-05-01
US20230149415A1 (en) 2023-05-18
WO2021202780A3 (en) 2021-11-11
CN115769077A (zh) 2023-03-07
MX2022012181A (es) 2023-01-30
AU2021249111A1 (en) 2022-10-20
CA3173799A1 (en) 2021-10-07
EP4127722A2 (en) 2023-02-08
KR20230017167A (ko) 2023-02-03

Similar Documents

Publication Publication Date Title
JP2023519931A (ja) 癌を治療するための方法及び組成物
Yang et al. Molecular mechanisms of platinum‑based chemotherapy resistance in ovarian cancer
Wang et al. AKT hyperactivation and the potential of AKT-targeted therapy in diffuse large B-cell lymphoma
US20210171958A1 (en) Methods of treating cancer
Dai et al. The anti-chemoresistant effect and mechanism of MUC1 aptamer–miR-29b chimera in ovarian cancer
Tong et al. A novel CREB5/TOP1MT axis confers cisplatin resistance through inhibiting mitochondrial apoptosis in head and neck squamous cell carcinoma
Hwang et al. Tumor suppressive functions of hsa‑miR‑34a on cell cycle, migration and protective autophagy in bladder cancer
WO2015127234A1 (en) Use of ibrutinib to treat egfr mutant cancer
Andrade et al. The DNA methyltransferase inhibitor zebularine exerts antitumor effects and reveals BATF2 as a poor prognostic marker for childhood medulloblastoma
El-Daly et al. Enhancement of the antitumor effect of 5-fluorouracil with modulation in drug transporters expression using PI3K inhibitors in colorectal cancer cells
EP3891285A1 (en) Aptamers and the use thereof in the treatment of cancer
Miao et al. PEDF inhibits non-small cell lung cancer proliferation by suppressing autophagy through downregulation of AMPK-ULK1 signaling
EP3606536A1 (en) Biomarkers indicative of prostate cancer and treatment thereof
CA2816929C (en) Synthetic lethality in cancer
Lin et al. The NEDD8-activating enzyme E1 UBA3 orchestrates the immunosuppressive microenvironment in lung adenocarcinoma via the NF-кB pathway
KR20140135198A (ko) Pak1 억제제로 흑색종을 치료하는 방법
WO2018228990A1 (en) Cyclin dependent kinase 4/6 inhibitors for use in methods of treating cancer
HK40089758A (zh) 用於治疗癌症的方法和组合物
Wilczyński et al. “DEPHENCE” system—a novel regimen of therapy that is urgently needed in the high-grade serous ovarian cancer—a focus on anti-cancer stem cell and anti-tumor microenvironment targeted therapies
WO2017203042A1 (en) Methods for treating smarcb1 deficient cancer or pazopanib resistant cancer
WO2021206633A1 (en) Methods and compositions for treating liver cancer
Subapriya et al. Targeting aberrant replication and DNA repair events for treating breast cancers
Patel Women in Skin Cancer: 2021
Lin et al. Molecular Mechanism of TMEM126A Modulating PANoptosis and Proliferation via TRAF6/NF-κB Signalling Pathway in Non-Small Cell Lung Cancer
Pan et al. Lysine methylation-mediated SMYD2 degradation by casticin sensitizes non-small-cell lung cancer cells to osimertinib therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240401

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240401

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250417

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250717

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250912

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251017

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20251017

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260123